Dianthus Therapeutics filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 643,599 shares of Common Stock, representing 1.2% of the class as of the close of business on March 31, 2026.
The filing identifies Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as the reporting persons; the shares are held through an investment fund managed by Point72 and are reported as shared voting and dispositive power. The percentage basis is an aggregate of 52,942,083 Shares outstanding derived from offering and prior outstanding counts disclosed in the filing.
Positive
None.
Negative
None.
Insights
Point72 reports a passive 1.2% stake in Dianthus as of March 31, 2026.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 643,599 shares via an investment fund they manage, with shared voting and dispositive power. The filing is an amendment to a Schedule 13G/A and states the calculation basis as 52,942,083 Shares outstanding.
Because the position is under 5%, it is reported under Schedule 13G/A conventions; cash‑flow treatment and sale intent are not stated in the excerpt and holder decisions will determine any future trading activity.
Key Figures
Shares beneficially owned:643,599 sharesPercent of class:1.2%Aggregate shares outstanding (basis):52,942,083 Shares+1 more
4 metrics
Shares beneficially owned643,599 sharesreported as of <date>March 31, 2026</date>
Percent of class1.2%calculated on 52,942,083 aggregate Shares outstanding
Aggregate shares outstanding (basis)52,942,083 Sharessum of offering, overallotment exercise, and prior outstanding counts
Reporting dateMarch 31, 2026ownership amounts as of close of business
"Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Shared Dispositive Powerfinancial
"Shared Dispositive Power 643,599.00"
Beneficial Ownershipregulatory
"Amount beneficially owned: The information required by Item 4(a)"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Dianthus Therapeutics, Inc. /DE/
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
252828108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
252828108
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
643,599.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
643,599.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
643,599.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
252828108
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
643,599.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
643,599.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
643,599.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
252828108
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
643,599.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
643,599.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
643,599.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
1.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Dianthus Therapeutics, Inc. /DE/
(b)
Address of issuer's principal executive offices:
7 Times Square, 43rd Floor, New York, NY 10036
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Shares"), of Dianthus Therapeutics, Inc. (the "Issuer") held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Cubist Systematic Strategies, LLC is a relying adviser on the Form ADV of Point72 Asset Management and acts as a sub-advisor with respect to a portion of the Shares reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
252828108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 52,942,083 Shares outstanding, which is the sum of (i) 7,313,582 Shares issued in the offering described in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission (the "SEC") on March 11, 2026; (ii) 1,157,407 Shares issued pursuant to the exercise of the underwriters' overallotment option as reported in the Issuer's Current Report on Form 8-K filed with the SEC on March 12, 2026; and (iii) 44,471,094 Shares outstanding as of March 4, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 9, 2026.
(b)
Percent of class:
1.2%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Point72 report in Dianthus Therapeutics (DNTH)?
Point72 reports beneficial ownership of 643,599 shares, equal to 1.2% of the class, as of the close of business on March 31, 2026. The shares are held through an investment fund managed by Point72.
Who are the reporting persons on the Schedule 13G/A for DNTH?
The filing names Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons, with Point72 Asset Management acting as investment manager for the fund holding the shares.
How was the 1.2% ownership percentage calculated?
The percentage is calculated using an aggregate of 52,942,083 Shares outstanding, which the filing derives from the issuer's recent offering, an underwriter overallotment exercise, and previously reported outstanding shares.
Does the filing show who receives proceeds or whether Point72 plans to sell shares?
The excerpt states shared voting and dispositive power but does not disclose cash‑flow treatment or any sale intent. The filing notes fund management relationships; future transactions are not specified in the provided text.
Are the reported shares directly owned by Steven A. Cohen?
No. The filing states that the reporting persons own directly no shares; Mr. Cohen controls the adviser entities that report shared voting and dispositive power over the fund's holdings of 643,599 shares.
